Scope
This summary covers NICE guideline NG130 on managing ulcerative colitis. The document has recommendations dated 2008, 2013, 2019 and 2025. Topics include patient information, inducing remission in mild-to-moderate disease by extent (proctitis, proctosigmoiditis or left-sided disease, extensive disease), moderately to severely active disease, and acute severe ulcerative colitis. It also covers information for people considering surgery, maintaining remission, pregnancy, treatment safety monitoring, bone health, and growth and pubertal monitoring in children and young people. For many advanced therapies, the guideline refers readers to separate NICE technology appraisals.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Patient information and support
- Discuss the disease, symptoms, treatment options and monitoring at every opportunity. Do this with the person (and family or carers where appropriate) and within a multidisciplinary team suited to the person's age. Also discuss possible drug side effects. Give information on colorectal cancer risk and colonoscopic surveillance. [1]
Inducing remission: mild-to-moderate disease
- Proctitis (first presentation or exacerbation), first line: offer a topical aminosalicylate. If there is no remission within 4 weeks, consider adding an oral aminosalicylate. If more treatment is needed, consider adding a time-limited topical or oral corticosteroid. If topical aminosalicylate is declined, consider an oral aminosalicylate instead and explain that it is less effective. Then consider a time-limited corticosteroid if there is no remission within 4 weeks. If aminosalicylates are not tolerated, consider a time-limited topical or oral corticosteroid. [1]
- Proctosigmoiditis or left-sided disease, first line: offer a topical aminosalicylate. If there is no remission within 4 weeks, consider either adding a high-dose oral aminosalicylate, or switching to a high-dose oral aminosalicylate plus a time-limited topical corticosteroid. If more treatment is needed, stop topical therapy and offer an oral aminosalicylate with a time-limited oral corticosteroid. [1]
- Proctosigmoiditis or left-sided disease, alternatives: if all topical treatment is declined, consider a high-dose oral aminosalicylate alone and explain that it is less effective. Offer an added time-limited oral corticosteroid if there is no remission within 4 weeks. If aminosalicylates are not tolerated, consider a time-limited topical or oral corticosteroid. [1]
- Extensive disease, first line: offer a topical aminosalicylate plus a high-dose oral aminosalicylate. If there is no remission within 4 weeks, stop the topical agent and offer a high-dose oral aminosalicylate with a time-limited oral corticosteroid. If aminosalicylates are not tolerated, consider a time-limited oral corticosteroid. [1]
- Definitions: a time-limited oral corticosteroid course normally lasts 4 to 8 weeks, depending on the steroid. Severity is graded by the Truelove and Witts' index in adults and by PUCAI in children and young people. PUCAI bands: 65 or above is severe, 35 to 64 moderate, 10 to 34 mild, and below 10 remission. [1]
Moderately to severely active disease
- General principles for advanced therapies. When several medicines are suitable, discuss the pros and cons of each option. Then use the least expensive, taking into account administration costs, dosages, price per dose and commercial arrangements. Continue listed medicines until they stop working or surgery is needed, and reassess at least every 12 months. The guideline also signposts MHRA safety advice on JAK inhibitors (April 2023). [1]
- Adults in whom conventional treatment has failed or is not tolerated: NICE technology appraisals list etrasimod, upadacitinib, filgotinib, tofacitinib and vedolizumab as options. [1]
- Adults in whom conventional treatment has failed or is not tolerated: the same appraisal list also includes infliximab, adalimumab and golimumab as options. [1]
- Adults in whom a TNF-alpha inhibitor is unsuitable, has failed or is not tolerated: the appraisal options are guselkumab, risankizumab, mirikizumab, ozanimod, ustekinumab and vedolizumab. [1]
- Adults in whom previous biological treatment has failed or is not tolerated: the appraisal options are etrasimod, upadacitinib, ozanimod, filgotinib and tofacitinib. [1]
- Children and young people: some adult options may be available under NHS England specialised commissioning policy. Etrasimod is an option at ages 16 and 17 years for moderately to severely active disease after inadequate or lost response to, or intolerance of, conventional or biological treatment. Infliximab is an option at ages 6 to 17 years for severely active disease when conventional treatment has responded inadequately, is not tolerated or is contraindicated. [1]
Acute severe ulcerative colitis
- For admitted patients, a gastroenterologist and a colorectal surgeon should manage care together, within an age-appropriate team. Seek advice from a paediatric gastroenterology expert for children. Include obstetrics and gynaecology for pregnant women. [1]
- Initial therapy for admitted patients (first presentation or exacerbation): offer intravenous corticosteroids and assess the likelihood of surgery. If IV corticosteroids are not tolerated, are declined or are contraindicated, consider IV ciclosporin or surgery, guided by the person's preferences. Ciclosporin use was off-label as of May 2019. [1]
- Next step: if there is little or no improvement within 72 hours of starting IV corticosteroids, or symptoms worsen at any time, consider adding IV ciclosporin or consider surgery, taking preferences into account. Infliximab is an option for acute severe exacerbations only when ciclosporin is contraindicated or clinically inappropriate, after careful individual risk–benefit assessment. [1]
- Assess and document the likelihood of surgery on admission and then daily. Listed features that may signal a higher likelihood include more than 8 stools per day, colonic dilatation on abdominal X-ray, low albumin, low haemoglobin, high platelets, or CRP above 45 mg/litre. Normal values may differ in pregnancy. [1]
Information for people considering surgery
- A specialist should explain all available treatment options, including their benefits and risks and the consequences of no treatment, and allow enough time to consider them. A colorectal surgeon should explain what to expect in the short and long term after surgery. [1]
- Provide information on sexual function, lifestyle effects, psychological wellbeing, the type of surgery and the possibility of a stoma. Explain stoma siting and care. After surgery, give information on managing bowel function that is specific to an ileostomy or an ileoanal pouch. [1]
Maintaining remission
- After a mild-to-moderate exacerbation of proctitis or proctosigmoiditis, consider (according to preference) one of three options: a topical aminosalicylate alone, daily or intermittent; an oral plus a topical aminosalicylate; or an oral aminosalicylate alone. If oral alone is chosen, explain it may be less effective. [1]
- Left-sided or extensive disease after a mild-to-moderate exacerbation: offer adults a low maintenance dose of an oral aminosalicylate. Offer children an oral aminosalicylate dosed by body weight per the BNF. Choose the agent by preference, side effects and cost. Consider once-daily dosing, explaining that it can be more effective but may cause more side effects. [1]
- Consider oral azathioprine or mercaptopurine after 2 or more exacerbations within 12 months needing systemic corticosteroids, or if aminosalicylates fail to maintain remission. After a single acute severe episode, consider azathioprine or mercaptopurine. Consider oral aminosalicylates if these are contraindicated or not tolerated. [1]
Pregnancy and monitoring
- In pregnancy, ensure communication and information-sharing across specialties. Discuss the risks and benefits of treating versus not treating to induce or maintain remission, including the possibility of admission for an acute severe exacerbation. [1]
- Have documented local safety monitoring policies, including audit, and a named staff member who acts on abnormal results and communicates with GPs. For adult fracture risk, follow NICE osteoporosis guidance. Consider bone health monitoring in children during chronic active disease, after systemic corticosteroids, or after recurrent active disease. [1]
- Plot children's height and weight on centile charts or z scores. Monitor every 3 to 6 months during an exacerbation around puberty, chronic active disease or systemic corticosteroid use. Monitor every 6 months during pubertal growth with inactive disease, and otherwise every 12 months. [1]
- Assess puberty using Tanner staging principles. Consider referral to a secondary care paediatrician if pubertal progress is slow or age-appropriate features have not developed. Allow self-assessment if the young person prefers it, where possible. [1]
Limitations and use
- Research recommendations and most committee rationale sections are excluded from this summary.
- Several adult and paediatric advanced-therapy recommendations refer to separate NICE technology appraisals; their eligibility criteria and details are not reproduced here.
- Most evidence for mild-to-moderate induction came from adults; the committee generalised the recommendations to all ages. Several aminosalicylate, azathioprine, mercaptopurine and ciclosporin uses were noted as off-label (as of May 2019), particularly in children.
- The list of features suggesting increased likelihood of surgery in acute severe ulcerative colitis (rec 1.2.27) also includes clinical signs not reproduced in this summary; consult the original recommendation.
- The Truelove and Witts' table and the PUCAI scoring items are only partly summarised; consult the original tables.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Ulcerative colitis: management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 3 May 2019
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.